Connect Sign In
Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine
Ordering Recommendation
Qualitative test to monitor medication compliance and to detect undisclosed drug/substance use in support of pain management, substance use disorders treatment, and other pharmacotherapies involving controlled substances.
If expert result interpretation is desired, refer to Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288). For a traditional screen with reflex to secondary quantitative testing, refer to Drug Profile, Screen with Reflex to Quantitation (2012312).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 4 mL each into two (2) ARUP standard transport tubes of urine with no additives or preservatives. (Min: 2 mL each)
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month
Methodology
Qualitative Tandem Mass Spectrometry/Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Qualitative Spectrophotometry
Performed
Sun-Sat
Reported
1-3 days
Reference Interval
Drugs covered and range of cutoff concentrations. Note: Some drugs are identified based on the presence of unique drug metabolites not listed below. |
|
|---|---|
| Drugs/Drug Classes |
Range of Cutoff Concentrations |
| Barbiturates | 200 ng/mL |
| Benzodiazepine-like: alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem |
20 - 60 ng/mL |
| Cannabinoids (11-nor-9-carboxy-THC) | 50 ng/mL |
| Ethyl Glucuronide | 500 ng/mL |
| Muscle Relaxant(s): carisoprodol, meprobamate |
100 ng/mL |
| Opiates/Opioids: buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol |
2-200 ng/mL |
| GABA analogues: Gabapentin, pregabalin |
3,000 ng/mL |
| Phencyclidine (PCP) | 25 ng/mL |
| Stimulants: amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine |
50-200 ng/mL |
Interpretive Data
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
Note
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Hotline History
Hotline History
CPT Codes
80326; 80347; 80364; 80355; 80307 (Alt code: G0481)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0090386 | Creatinine, Urine | 2161-8 |
| 2007636 | Codeine, U | 3507-1 |
| 2007637 | Morphine, U | 3830-7 |
| 2007638 | 6-acetylmorphine, U | 10976-9 |
| 2007640 | Oxycodone, U | 10998-3 |
| 2007641 | Noroxycodone, U | 61424-8 |
| 2007642 | Oxymorphone, U | 11247-4 |
| 2007643 | Noroxymorphone, U | 89302-4 |
| 2007644 | Hydrocodone, U | 12308-3 |
| 2007646 | Norhydrocodone, U | 61421-4 |
| 2007647 | Hydromorphone, U | 9834-3 |
| 2007649 | Buprenorphine, U | 3414-0 |
| 2007651 | Norbuprenorphine, U | 58362-5 |
| 2007652 | Fentanyl, U | 11235-9 |
| 2007653 | Norfentanyl, U | 43199-9 |
| 2007654 | Meperidine metabolite, U | 58388-0 |
| 2007655 | Tapentadol, U | 72485-6 |
| 2007656 | Tapentadol-o-Sulf, U | 72485-6 |
| 2007658 | Methadone Screen, U | 3773-9 |
| 2007660 | Tramadol Screen, U | 43219-5 |
| 2007662 | Amphetamine, U | 19343-3 |
| 2007663 | Methamphetamine, U | 3779-6 |
| 2007664 | MDMA, U | 14267-9 |
| 2007665 | MDA, U | 42253-5 |
| 2007666 | MDEA, U | 61048-5 |
| 2007668 | Phentermine, U | 3957-8 |
| 2007670 | Cocaine Screen, U | 3393-6 |
| 2007672 | Alprazolam, U | 9351-8 |
| 2007673 | Alpha-OH-Alprazolam, U | 61036-0 |
| 2007674 | Clonazepam, U | 19245-0 |
| 2007675 | 7-Aminoclonazepam, U | 61030-3 |
| 2007676 | Diazepam, U | 3550-1 |
| 2007677 | Nordiazepam, U | 3861-2 |
| 2007678 | Oxazepam, U | 12361-2 |
| 2007679 | Temazepam, U | 61060-0 |
| 2007680 | Lorazepam, U | 18187-5 |
| 2007681 | Midazolam, U | 19585-9 |
| 2007682 | Zolpidem, U | 33338-5 |
| 2007684 | Barbiturates Screen, U | 3377-9 |
| 2007687 | Ethyl Glucuronide Screen, U | 55349-5 |
| 2007688 | THC (Cannabinoids) Screen, U | 3435-5 |
| 2007689 | Phencyclidine Screen, U | 3936-2 |
| 2007690 | Carisoprodol Screen, U | 21142-5 |
| 2007691 | Targeted Drug Profile Comment | 8251-1 |
| 2008312 | EER Targeted Drug Profile, U | 11526-1 |
| 2013281 | Methylphenidate, U | 3808-3 |
| 3003499 | Alpha-OH-Midazolam, U | 94108-8 |
| 3003500 | Zolpidem Metabolite, U | 94103-9 |
| 3003501 | Gabapentin, U | 92648-5 |
| 3003502 | Naloxone, U | 92649-3 |
| 3003503 | Pregabalin, U | 92651-9 |
Aliases
- abstinence verification
- addiction management
- Comprehensive hybrid
- drug screen
- high res
- high-res
- hybrid
- medication adherence
- medication compliance
- Pain management
- prenatal drug screen
- substance use disorder
- targeted
- urine
